Digestive and Liver Disease

Papers
(The H4-Index of Digestive and Liver Disease is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?73
Pharmacologic venous thromboembolism prophylaxis is not associated with post sphincterotomy bleeding after endoscopic retrograde cholangiopancreatography65
Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAID62
Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU61
Author's Reply: “Dairy-Rich diets: A promising strategy for reducing the risk of metabolic liver disease”55
The burden of HDV infection: A ten-years’ experience of a sicilian tertiary centre of liver disease54
The potential role of machine learning in modelling advanced chronic liver disease50
Improvement of clinical parameters in HDV patients with advanced compensated cirrhosis treated with Bulevirtide monotherapy for 48 weeks43
Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosin-kinase inhibitors: a real-world analysis41
Isolated IgG4-related cholecystitis mimicking an advanced gallbladder cancer: Don't fall into the trap39
Factors associated with prior acute pancreatitis episodes37
Thrombopoietin receptor agonists before elective invasive procedures in cirrhotic patients with thrombocytopenia: ready to start?36
Association between remnant cholesterol and metabolic dysfunction-associated steatotic liver disease in the elderly36
Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world study34
Evolution of hepatic encephalopathy over time: ecological data from a tertiary referral centre for hepatology31
Giant gastric myxoid epithelioid gastrointestinal stromal tumor30
Metastatic hepatocellular carcinoma cured by exclusive systemic antiangiogenic therapy: Two cases along with tumor molecular profiles29
Editorial Board28
Subepithelial lesions in the distal esophagus28
[¹¹C] choline as a potential PET/CT biomarker of liver cirrhosis: A prospective pilot study28
Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis27
Reply to: “Inflammatory bowel disease epidemiology data from a prospective registry in Córdoba, Argentina: Raising the bar for future studies in Latin America”.27
Bacterial infections as a risk factor for non-neoplastic portal vein thrombosis development in cirrhotic patients26
T.03.2 EXPLORING A NOVEL COMPOSITE DIAGNOSTIC TOOL USING NON-CONTRAST EUS ENHANCED CYST WALL MICROVASCULAR IMAGING AND CYST FLUID ANALYSIS TO DIFFERENTIATE PANCREATIC CYSTIC NEOPLASMS25
OC.10.8 DISHEVELLED-ASSOCIATED ANTAGONIST OF B-CATENIN 2 (DACT2) IN PANCREATIC DUCTAL ADENOCARCINOMA24
OC.10.3 LUMEN-APPOSING METAL STENTS FOR EUS-GUIDED DRAINAGE OF WALLED-OFF PANCREATIC NECROSIS: RESULTS OF A LARGE MULTICENTER COHORT24
0.14561605453491